Cargando…
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453660/ https://www.ncbi.nlm.nih.gov/pubmed/25584489 http://dx.doi.org/10.1038/bjc.2014.649 |
_version_ | 1782374495644811264 |
---|---|
author | Zhu, M Tang, R Doshi, S Oliner, K S Dubey, S Jiang, Y Donehower, R C Iveson, T Loh, E Y Zhang, Y |
author_facet | Zhu, M Tang, R Doshi, S Oliner, K S Dubey, S Jiang, Y Donehower, R C Iveson, T Loh, E Y Zhang, Y |
author_sort | Zhu, M |
collection | PubMed |
description | BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival, especially in MET-positive patients, but no clear dose–response relationship was observed. Exposure-response and biomarker analyses were used for dose selection and to differentiate patient subpopulations that may benefit most from treatment. Here, we analyse rilotumumab exposure–survival and exposure–safety and the impact of MET expression on these relationships. METHODS: Individual rilotumumab exposure parameters were generated using population pharmacokinetic modelling. Relationships among rilotumumab dose (7.5 and 15 mg kg(−1)), exposure, and clinical outcomes (progression-free survival (PFS) and overall survival (OS)) were evaluated with Cox regression models and Kaplan–Meier plots. MET status and other baseline covariates were evaluated in subgroup and multivariate analyses. Treatment-emergent adverse events were summarised by exposure. RESULTS: Among MET-positive patients, higher rilotumumab exposure, vs placebo and low exposure, was associated with improved median PFS (80% CI: 7.0 (5.7–9.7) vs 4.4 (2.9–4.9) and 5.5 (4.2–6.8) months) and OS (13.4 (10.6–18.6) vs 5.7 (4.7–10.2) and 8.1 (6.9–11.1) months) without increased toxicity. No rilotumumab benefit was seen among MET-negative patients. CONCLUSIONS: Rilotumumab had an exposure-dependent treatment effect in patients with MET-positive gastric or oesophagogastric junction cancer. |
format | Online Article Text |
id | pubmed-4453660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44536602016-02-03 Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression Zhu, M Tang, R Doshi, S Oliner, K S Dubey, S Jiang, Y Donehower, R C Iveson, T Loh, E Y Zhang, Y Br J Cancer Clinical Study BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival, especially in MET-positive patients, but no clear dose–response relationship was observed. Exposure-response and biomarker analyses were used for dose selection and to differentiate patient subpopulations that may benefit most from treatment. Here, we analyse rilotumumab exposure–survival and exposure–safety and the impact of MET expression on these relationships. METHODS: Individual rilotumumab exposure parameters were generated using population pharmacokinetic modelling. Relationships among rilotumumab dose (7.5 and 15 mg kg(−1)), exposure, and clinical outcomes (progression-free survival (PFS) and overall survival (OS)) were evaluated with Cox regression models and Kaplan–Meier plots. MET status and other baseline covariates were evaluated in subgroup and multivariate analyses. Treatment-emergent adverse events were summarised by exposure. RESULTS: Among MET-positive patients, higher rilotumumab exposure, vs placebo and low exposure, was associated with improved median PFS (80% CI: 7.0 (5.7–9.7) vs 4.4 (2.9–4.9) and 5.5 (4.2–6.8) months) and OS (13.4 (10.6–18.6) vs 5.7 (4.7–10.2) and 8.1 (6.9–11.1) months) without increased toxicity. No rilotumumab benefit was seen among MET-negative patients. CONCLUSIONS: Rilotumumab had an exposure-dependent treatment effect in patients with MET-positive gastric or oesophagogastric junction cancer. Nature Publishing Group 2015-02-03 2015-01-13 /pmc/articles/PMC4453660/ /pubmed/25584489 http://dx.doi.org/10.1038/bjc.2014.649 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Zhu, M Tang, R Doshi, S Oliner, K S Dubey, S Jiang, Y Donehower, R C Iveson, T Loh, E Y Zhang, Y Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
title | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
title_full | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
title_fullStr | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
title_full_unstemmed | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
title_short | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
title_sort | exposure-response analysis of rilotumumab in gastric cancer: the role of tumour met expression |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453660/ https://www.ncbi.nlm.nih.gov/pubmed/25584489 http://dx.doi.org/10.1038/bjc.2014.649 |
work_keys_str_mv | AT zhum exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT tangr exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT doshis exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT olinerks exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT dubeys exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT jiangy exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT donehowerrc exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT ivesont exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT lohey exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression AT zhangy exposureresponseanalysisofrilotumumabingastriccancertheroleoftumourmetexpression |